

MEDIA ADVISORY

For Immediate Release – May 28, 2007

FOSAMAX CLASS ACTION COMMENCED IN CANADA

LONDON, ONTARIO – The law firm Siskinds ^{LLP} launched a class action today against Merck Frosst Canada ("Merck") regarding its osteoporosis drug Fosamax.

Fosamax was approved for sale in Canada in 1995. Since then, sales of Fosamax for the treatment of osteoporosis and Paget's disease have been strong.

Use of Fosamax has been linked to an increased risk of developing Osteonecrosis of the jaw ("ONJ"), also known as "jaw death". ONJ can be extremely painful and can cause jaw bones to rot and die. Merck is now warning consumers about the possibility of developing ONJ and Health Canada is monitoring the situation.

The Statement of Claim alleges that Merck failed to adequately warn patients and physicians that Fosamax has been associated with an increased risk of developing ONJ. Michael Peerless, a partner with Siskinds ^{LLP}, says "We believe that through this lawsuit Merck will be required to explain to Canadian consumers what it knew about the risks associated with Fosamax and when it first became aware of those risks. In this case, as with all of these types of cases, we are concerned about whether Canadians were adequately warned of the risks associated with using the product in question."

It is too early at this stage to quantify the claims of potential class members, but it is anticipated that the amount is significant. Canadians using Fosamax are encouraged to visit www.classaction.ca or to call 1-800-461-6166. Quebec residents can contact Claude Desmeules at (418) 694-2009.

For further information: Please contact Michael Peerless at (519) 660-7866.